Celgene’s Amrubicin Gains Orphan Status
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III anthracycline targets small cell lung cancer.
You may also be interested in...
Vidaza Key To Celgene’s $2.9 Billion Pharmion Purchase
Celgene gains first myelodysplastic syndromes therapy to show survival benefit in high-risk patients, as well as full control of multiple myeloma therapy thalidomide and late-stage candidates.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.